J. Hanson

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Matthew A. Wiles, Manisha, Christopher M. Horvat, 2021, Intensive Care Medicine.

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Matthew A. Wiles, Nerissa C. Brown, Christopher M. Horvat, 2022, JAMA.

O‐02: Prevalence of hepatitis B, hepatitis C and hepatitis D virus infections in Cameroon: results from a national population based survey (The ANRS 12289 project)

M. Emmert-Buck, D. Anderson, F. Zamboni, 2015 .

Identification of a unique epigenetic sub‐microenvironment in prostate cancer

J. Gillespie, M. Emmert-Buck, S. Libutti, 2007, The Journal of pathology.

Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C)

G. Dore, M. Martinello, G. Matthews, 2023, Journal of viral hepatitis.